Showing 23 Results
NPC Submits Comments to CMS on Medicaid Drug Rebate Program
In this comment letter, NPC weighs in on CMS' proposed rule changes to the Medicaid Drug Rebate Program (MDRP).
Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry
New study examines the role of NIH and industry in bringing new treatments into clinical settings.
NPC Comments on CMS' Drug Price Negotiation Counteroffer Information Collection Request
As CMS develops the detailed steps involved in the agency's drug pricing processes, NPC's comments highlight key shortcomings in the agency's counteroffer information collection request (ICR).
NPC Comments on CMS Information Collection Request for Negotiation Data Elements
NPC's comments offer input on the agency's latest efforts to implement the drug price-setting provisions of the Inflation Reduction Act through the design of a data collection process.
NPC Comments on CMS Medicare Drug Price Negotiation Program
NPC's comments highlight concerns about the agency's guidance regarding the implementation of Medicare Drug Price Negotiation and the potential for unintended consequences, including less…
What Might Have Happened: The Impact of Interrupting Entry of Innovative Drugs on Disease Outcomes in the United States
A new NPC study shows how major drug innovations significantly improved patient health outcomes for six diseases with substantial mortality or morbidity.
Affordability Is About More Than Drug Prices
A research survey from NPC and Xcenda found that potential government involvement in drug pricing would be unlikely to increase patient affordability.
The Impact of COVID-19 on Real-World Health Data and Research
This white paper provides key health care stakeholders, including clinicians, researchers, payers and regulators, with a broad view of how the COVID-19 pandemic may have impacted real-world data (RWD…
Health Plan Use of Patient Data: From the Routine to the Transformational
As the abundance and variety of patient data elements and sources continue to grow, health plans seek opportunities to deepen insights from multiple sources of patient data to shape care delivery,…
A Dynamic Approach to Consumer Cost-Sharing for Prescription Drugs
The level of consumer cost-sharing for higher cost medication should be aligned with the clinical value – not solely the price – when lower cost alternatives do not produce the desired patient…
Data, Data Everywhere, But Access Remains a Big Issue for Researchers
This study captures the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers. These limitations can make it harder to conduct high…
Why Is Broader Access to Publicly Funded Data Important?
This infographic illustrates the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers.
When Does FDAMA Section 114 Apply? Ten Case Studies
There is hesitation to disseminate comparative effectiveness research because of ambiguities in the law that was established to help biopharmaceutical companies engage health plans around real-world…
Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice
This study suggests that changes are needed to enable more consistent translation of research findings into clinical practice.
Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design
Value-based insurance design (V-BID) is a key tactic payers and purchasers can use to promote access to high-value specialty medications.